These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 28438091)

  • 21. The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions.
    Mavi A; Cermik TF; Urhan M; Puskulcu H; Basu S; Yu JQ; Zhuang H; Czerniecki B; Alavi A
    J Nucl Med; 2007 Aug; 48(8):1266-72. PubMed ID: 17631558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu.
    Halilovic A; Bulte J; Jacobs Y; Braam H; van Cleef P; Schlooz-Vries M; Werner A; Boelens O; Nagtegaal I; de Wilt H; Bult P
    J Clin Pathol; 2017 Sep; 70(9):781-786. PubMed ID: 28325747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
    Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
    Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of oestrogen and progesterone receptors, and c-erbB-2 in carcinoma of the breast in Trinidadian women.
    Rao AV; Mohammed WA; Ragoonanan C; Omo-Igbinomwanhia NE
    West Indian Med J; 2002 Mar; 51(1):4-9. PubMed ID: 12089875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The association of infrared imaging findings of the breast with hormone receptor and human epidermal growth factor receptor 2 status of breast cancer.
    Wang J; Shih TT; Yen RF; Lu YS; Chen CY; Mao TL; Lin CH; Kuo WH; Tsai YS; Chang KJ; Chien KL
    Acad Radiol; 2011 Feb; 18(2):212-9. PubMed ID: 21126889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tissue microarray (TMA) versus whole section immunohistochemistry in the assessment of ER/PR and Her-2/neu status in a breast cancer series from Sudan.
    Awadelkarim KD; Arizzi C; Elamin EO; Osman I; Mekki SO; Biunno I; Barberis MC; Mariani-Costantini R
    Breast J; 2013; 19(4):446-7. PubMed ID: 23721068
    [No Abstract]   [Full Text] [Related]  

  • 27. Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.
    Van Belle V; Van Calster B; Brouckaert O; Vanden Bempt I; Pintens S; Harvey V; Murray P; Naume B; Wiedswang G; Paridaens R; Moerman P; Amant F; Leunen K; Smeets A; Drijkoningen M; Wildiers H; Christiaens MR; Vergote I; Van Huffel S; Neven P
    J Clin Oncol; 2010 Sep; 28(27):4129-34. PubMed ID: 20713855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results with accelerated partial breast irradiation in terms of estrogen receptor, progesterone receptor, and human growth factor receptor 2 status.
    Wilder RB; Curcio LD; Khanijou RK; Eisner ME; Kakkis JL; Chittenden L; Agustin J; Lizarde J; Mesa AV; Macedo JC; Ravera J; Tokita KM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):799-803. PubMed ID: 20869583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
    Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A
    Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramatically increases health care costs.
    VandenBussche CJ; Cimino-Mathews A; Park BH; Emens LA; Tsangaris TN; Argani P
    Am J Surg Pathol; 2015 Jul; 39(7):939-47. PubMed ID: 25871620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer.
    Cubukcu E; Kanat O; Fatih Olmez O; Kabul S; Canhoroz M; Avci N; Deligonul A; Hartavi M; Cubukcu S; Olmez F; Kurt E; Evrensel T; Gokgoz S; Manavoglu O
    J BUON; 2013; 18(2):359-65. PubMed ID: 23818346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stability of oestrogen and progesterone receptor antigenicity in formalin-fixed paraffin-embedded breast cancer tissue over time.
    Ehinger A; Bendahl PO; Rydén L; Fernö M; Alkner S
    APMIS; 2018 Sep; 126(9):746-754. PubMed ID: 30160021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of immunohistochemical tests in multimodal treatment of the aggressive forms of breast cancer.
    Mihai D; Voiculescu S; Dimitriu C; Constantinescu F; Stanilescu S; Burcos T
    J Med Life; 2014; 7 Spec No. 2(Spec Iss 2):58-64. PubMed ID: 25870675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
    Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
    Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).
    Słodkowska J; Filas V; Buszkiewicz E; Trzeciak P; Wojciechowski M; Koktysz R; Staniszewski W; Breborowicz J; Rojo MG
    Folia Histochem Cytobiol; 2010 Jan; 48(1):19-25. PubMed ID: 20529811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selecting an Optimal Positive IHC Control for Verifying Antigen Retrieval.
    Sompuram SR; Vani K; Schaedle AK; Balasubramanian A; Bogen SA
    J Histochem Cytochem; 2019 Apr; 67(4):275-289. PubMed ID: 30628843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interobserver reproducibility of immunocytochemical estrogen- and progesterone receptor status assessment in breast cancer.
    Biesterfeld S; Veuskens U; Schmitz FJ; Amo-Takyi B; Böcking A
    Anticancer Res; 1996; 16(5A):2497-500. PubMed ID: 8917341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fine needle aspirate cell blocks are reliable for detection of hormone receptors and HER-2 by immunohistochemistry in breast carcinoma.
    Bueno Angela SP; Viero RM; Soares CT
    Cytopathology; 2013 Feb; 24(1):26-32. PubMed ID: 22220518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.